1 withdrawn. 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Withdrawn 1 |
Follow Vascular Fistula: new trials by email Literature Review of Vascular Fistula trials Research Report on Vascular Fistula
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients 1.25mg bevacizumab, 2.50mg bevacizumab - End Stage Renal Disease, Hemodialysis Vascular Access Failure | Early Phase 1 | Withdrawn | Mayo Clinic | 2019-08-01 | 2026-06-24 |
Arteriovenous Fistula (1) · Kidney Failure, Chronic (1)
Arteriovenous Malformations (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fistula (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
Bevacizumab (1)
Mayo Clinic (1)
Sanjay Misra, MD (1)